Medication Risk Taking Behavior in IBS Patients

Lacy, Brian E.; Everhart, Kelly; Weiser, Kirsten; Lee, Ryan De; Strobel, Sebastian; Siegel, Corey A.; Crowell, Michael D.

doi:10.14309/00000434-200910003-01310

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several treatments are available, IBS remains a major public health problem worldwide. IBS symptoms substantially affect work, social relationships, and quality of life, leading to considerable comorbidities and health resource use (4)(5)(6)(7). It has been reported as the second leading cause of absence from work and/ or school (8).…”

Section: Introductionmentioning

confidence: 99%

Irritable Bowel Syndrome and Long-Term Risk of Cancer: A Prospective Cohort Study Among 0.5 Million Adults in UK Biobank

Yuan

Liu

et al. 2022

Am J Gastroenterol

View full text Add to dashboard Cite

INTRODUCTION: To investigate the prospective association of irritable bowel syndrome (IBS) with long-term risk of overall, site-specific cancer and cancer-specific mortality in general population. METHODS:Participants free of inflammatory bowel disease, celiac disease, and any cancer at baseline from the UK Biobank were included, with patients with IBS as the exposure group and non-IBS patients as the reference group. The primary outcome was the incidence of overall cancer and cancer-specific mortality. Secondary outcomes included site-specific cancers and types of digestive cancers. The Cox proportional hazard model was used to investigate the associated risk of incident malignancies and related mortality. RESULTS:Among 449,595 participants, 22,338 (5.0%) were diagnosed with IBS. During a median of 12.2-year follow-up, 2,937 cases of incident cancer were identified in patients with IBS (11.47 per 1,000 person-years), compared with 60,556 cases in reference individuals (12.51 per 1,000 person-years). Of these cases, 512 and 12,282 cancer-specific deaths occurred in IBS and non-IBS groups.Compared with non-IBS, the adjusted hazard ratio for overall cancer and cancer-specific mortality was 0.97 (95% confidence interval: 0.93-1.00, P 5 0.062) and 0.83 (0.76-0.91, P < 0.001) among patients with IBS. Specifically, decreased risk of digestive (0.79 [0.71-0.89]), particularly colon (0.75 [0.62-0.90]) and rectal (0.68 [0.49-0.93]), cancers was observed in patients with IBS. Further sensitivity analysis and subgroup analysis by age and sex indicated similar results. DISCUSSION:Compared with the general population, IBS does not increase the overall risk of cancer. Conversely, IBS is associated with lower risk of incident colorectal cancer and cancer-specific mortality.

show abstract

Section: Introductionmentioning

confidence: 99%

Irritable Bowel Syndrome and Long-Term Risk of Cancer: A Prospective Cohort Study Among 0.5 Million Adults in UK Biobank

Yuan

Liu

et al. 2022

Am J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…From the perspective of the patient with IBS, due to the limited therapeutic options available to them, many are willing to accept considerable risk of side effects for the possibility of receiving an efficacious treatment [Lacy et al 2009]. An online study conducted by the International Foundation for Functional Gastrointestinal Disorders in collaboration with the University of North Carolina Center for Functional GI and Motility Disorders found that patients with IBS would give up 25% of their remaining life (average 15 years), and 14% of patients would accept a 1 in 1000 chance of death to be symptom free [Drossman et al 2009].…”

mentioning

confidence: 99%

“…In summary, extensive data from alosetron clinical trials and postmarketing experience has shown: no increase in rates of IC, as feared in 2000, which remain consistently rare and stable over time; no deaths due to IC since reintroduction of alosetron in 2002; the risk management plan for alosetron having a high degree of compliance and effectiveness in mitigating IC and CoC; patients with IBS appear to be predisposed to developing IC with up to an eightfold increase in risk as demonstrated by epidemiological evidence; and patients with severe IBS-D are willing to accept some risks of side effects for a better quality of life [Lacy et al 2009].…”

mentioning

confidence: 99%